Multi-Corp International, Inc. MULI Company Overview

New Post Public Reply Private Reply Replies (0) Message Board

Aug 31, 2013 at 10:37 PM

Multi-Corp International, Inc. MULI Company Overview

Stock Message Board http://investorshangout.com/search?q=MULI&...mp;yt1=Go!

Multi-Corp International, Inc. MULI Current Price and Quotes
0.42
Previous Close
0.42
Open
0.42

Daily Range
0.42 - 0.35
52wk Range
1.69 - 0.02

Volume
23,000
Dividend
N/A

Average Vol (3m)
70,159
Yield
N/A

Multi-Corp International, Inc. MULI
Company Information
3651 Lindell Road, Suite D 414
Las Vegas, NV 89103

Website: http://www.multi-corpinternational.com
Phone: 702-483-2974

Multi-Corp International, Inc. MULI
Multi Corp International is an independent junior oil and gas exploration, development and production company headquartered in Los Angeles CA. The Company is duly incorporated in the State of Nevada. The Company's common shares are listed for trading on the electronic over-the-counter pink sheets (OTC-PINK) market in the United States and trades under the symbol "MULI".

Multi-Corp International, Inc. MULI
Financial Reportings and Disclosures
Reporting Status U.S. Reporting: SEC Filer
Audited Financials Audited
Latest Report Sep 30, 2012 10-Q
CIK 0001405260
Fiscal Year End 12/31
OTC Marketplace OTC Pink Limited
Profile Data
SIC - Industry Classification 1000 - Metal Mining
Business Status Development Stage Company a/o Aug 11, 2011
Incorporated In: NV, USA
Year of Inc. 2006
Employees Not Available
Company Officers/Contacts
Jean Mann CEO
Robert Baker President, CFO, Treasurer
Company Directors
Jean Mann
Company Notes
Formerly=Aquasil International, Inc. until 6-2012
Formerly=BWI Holdings, Inc. until 2-2011
Formerly=Gray Creek Mining, Inc. until 11-2008
Service Providers
Auditor/Accountant
M&K CPAS, PLLC
4100 North Sam Houston Pkwy W
Houston, TX, 77086
United States

Legal Counsel
Brinen & Associates, LLC
7 Dey Street
New York, NY, 10007
United States

Investor Relations Firm
Not Available

Multi-Corp International, Inc. MULI
MULI Security Details
Share Structure
Market Value1 $31,568,931 a/o Aug 30, 2013
Shares Outstanding 75,164,122 a/o Nov 15, 2012
Float Not Available
Authorized Shares Not Available
Par Value 0.001
Shareholders
Shareholders of Record 828 a/o Apr 16, 2012
Security Notes
Capital Change=shs increased by 5 for 1 split Ex-date=02/02/2009. Rec date=01/20/2009. Pay date=01/30/2009.
Capital Change=shs decreased by 1 for 10 split Pay date=08/16/2010.
Capital Change=shs decreased by 1 for 1000 split. Ex-date=06/22/2012.
Short Selling Data
Short Interest 80,339 (-12.33%)
Aug 15, 2013
Significant Failures to Deliver No
Transfer Agent(s)
Island Stock Transfer

Multi-Corp International, Inc. MULI Recent News

Jul 29, 2013 Multi-Corp International Announces The Completion of the Posting of the Blanket Bond
Jul 24, 2013 Multi-Corp International Announces Completion of Meetings for Soil Clean-up Processes
Jul 22, 2013 Multi-Corp International Announces Meetings Taking Place for Bonding and Orientation
Jul 16, 2013 Multi-Corp International Announces the Estimated Oil Production on the Double XX Property Gas Field in New Mexico
Jul 10, 2013 Multi-Corp International Announces They Have Received a Certificate of Operations from the State of New Mexico
Jul 8, 2013 Multi-Corp International Announces the Signing of the Purchase/Assignment Papers on Double XX Property in New Mexico
Jun 10, 2013 Multi-Corp International, Inc. (OTC:MULI) Announces It Signed An LOI With Petro Worth To Acquire The Rosevale Property.
Jun 4, 2013 Multi-Corp International, Inc. announces meeting with New Mexico State authorities upcoming

Multi-Corp International, Inc. MULI Financials
Period Ending Dec 31, 2011 Dec 31, 2010 Mar 31, 2010 Mar 31, 2009
Total Revenue - - 7,758 9,865
Cost of Revenue - - 5,749 6,704
Gross Profit - - 2,009 3,162
Operating Expenses
Research and Development - - - -
Sales, General and Admin. 220 10 1,668 2,857
Non-Recurring Items - - 136 (55)
Other - - 739 1,225
Operating Income (220) (10) (809) (1,236)
Income From Continuing Operations
Add'l Income/Expense Items - - 145 493
Earnings Before Interest and Tax (220) (10) (389) (371)
Interest Expense 1 - 275 371
Earnings Before Tax (221) (10) (664) (742)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (221) (10) (664) (742)
Non Recurring Events
Discontinued Operations - - 36 15
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (221) (10) (628) (728)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (221) (10) (628) (728)

MULI Multi-Corp International, Inc. Research DD Guide

MULI Multi-Corp International, Inc. Stock Message Board http://investorshangout.com/search?q=MULI&...mp;yt0=Go!
MULI Multi-Corp International, Inc. Stock Quote http://www.otcmarkets.com/stock/MULI/quote
MULI Multi-Corp International, Inc. Stock Chart http://www.otcmarkets.com/stock/MULI/chart
MULI Multi-Corp International, Inc. Company Info http://www.otcmarkets.com/stock/MULI/company-info
MULI Multi-Corp International, Inc. Recent News http://www.otcmarkets.com/stock/MULI/news
MULI Multi-Corp International, Inc. Financials http://www.otcmarkets.com/stock/MULI/financials
MULI Multi-Corp International, Inc. Filings and Disclosure http://www.otcmarkets.com/stock/MULI/filings
MULI Multi-Corp International, Inc. Short Sales http://www.otcmarkets.com/stock/MULI/short-sales
MULI Multi-Corp International, Inc. Insider Disclosure http://www.otcmarkets.com/stock/MULI/insider-transactions
MULI Multi-Corp International, Inc. Research Reports http://www.otcmarkets.com/stock/MULI/research
MULI Multi-Corp International, Inc. Summary http://finance.yahoo.com/q?s=MULI
MULI Multi-Corp International, Inc. Historical Prices http://finance.yahoo.com/q/hp?s=MULI+Historical+Prices
MULI Multi-Corp International, Inc. Interactive Chart http://finance.yahoo.com/echarts?s=MULI
MULI Multi-Corp International, Inc. Basic Chart http://finance.yahoo.com/q/bc?s=MULI+Basic+Chart
MULI Multi-Corp International, Inc. Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=MULI+Basic+Tech.+Analysis
MULI Multi-Corp International, Inc. Headlines http://finance.yahoo.com/q/h?s=MULI+Headlines
MULI Multi-Corp International, Inc. Press Releases http://finance.yahoo.com/q/p?s=MULI+Press+Releases
MULI Multi-Corp International, Inc. Company Profile http://finance.yahoo.com/q/pr?s=MULI+Profile
MULI Multi-Corp International, Inc. Key Statistics http://finance.yahoo.com/q/ks?s=MULI+Key+Statistics
MULI Multi-Corp International, Inc. Industry http://finance.yahoo.com/q/in?s=MULI+Industry
MULI Multi-Corp International, Inc. Major Holders http://finance.yahoo.com/q/mh?s=MULI+Major+Holders
MULI Multi-Corp International, Inc. Insider Transactions http://finance.yahoo.com/q/it?s=MULI+Insider+Transactions
MULI Multi-Corp International, Inc. Insider Roster http://finance.yahoo.com/q/ir?s=MULI+Insider+Roster
MULI Multi-Corp International, Inc. Income Statement http://finance.yahoo.com/q/is?s=MULI
MULI Multi-Corp International, Inc. Balance Sheet http://finance.yahoo.com/q/bs?s=MULI
MULI Multi-Corp International, Inc. Cash Flow http://finance.yahoo.com/q/cf?s=MULI+Cash+Flow&annual
MULI Multi-Corp International, Inc. Nasdaq http://www.nasdaq.com/symbol/MULI
MULI Multi-Corp International, Inc. Market Watch http://www.marketwatch.com/investing/stock/MULI
MULI Multi-Corp International, Inc. Bloomberg http://www.bloomberg.com/quote/MULI:US
MULI Multi-Corp International, Inc. Morningstar http://quotes.morningstar.com/stock/s?t=MULI
MULI Multi-Corp International, Inc. Bussinessweek http://investing.businessweek.com/research/st...icker=MULI
MULI Multi-Corp International, Inc. Barchart http://www.barchart.com/quotes/stocks/MULI
MULI Multi-Corp International, Inc. OTC Short Report http://otcshortreport.com/index.php?index=MULI
MULI Multi-Corp International, Inc. Investopedia http://www.investopedia.com/markets/stocks/MULI/?wa=0

List of all stock message boards and tickers for OTC BB Pinks & Penny Stocks http://investorshangout.com/board?categoryid=OTC

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Alaska's Insurance Maze: Coverage Over Cheap Policies

Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...

Apalutamide Boosts Outlook for Prostate Cancer Treatment

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

Darden Faces Class Action Over Reimbursement Failures

Class Action Puts Darden Restaurants in Legal Hot Seat Darden Restaurants, Inc. is staring down the barrel of a lawsuit that's as fiery as a grill on a Saturday night rush. The legal cavalry from Blumenthal Nordrehaug Bhowmik De Blouw LLP has stormed in with a class action complaint, aiming dead center at Darden for allegedly breaching the California Labor Code. In plain...

ASTS Faces Crucial Deadline Amidst Legal Turmoil

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Lilly's Sofe-M Shakes Up Ovarian Cancer Treatment

Ovarian Cancer Treatment Sees a New Challenger Alright, folks, Eli Lilly (NYSE:LLY) is stepping up with their latest findings in ovarian cancer treatment, and it's got plenty of people in a buzz. They've dropped new data for their investigational drug, Sofetabart mipitecan, or 'Sofe-M' for short, which targets this unrelenting disease with a punch that’s hard to ignore....

CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Likang's Bold Move: Cancer Immunotherapy at AD Summit

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

Taiwan Fuses Ancient TCM with Modern Bio Tech in 2026

The Dynamic Fusion of Heritage and Innovation When you think about it, mixing centuries-old herbal wisdom with today's cutting-edge biotech might sound like a plot twist, but that's exactly what's cooking in Taiwan. Over at SupplySide Global 2026 in Las Vegas, Taiwan's got something more than just traditional medicine to flaunt; it's showcasing an impressive fusion of...

Bio-Thera's New Data: A Game Changer for NSCLC?

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...